Brief: Gland Pharma Gets Tentative Approval From U.S. FDA For Latanoprostene Bunod Ophthalmic Solution
23/07/2024 10:26
July 23 (Reuters) - Gland Pharma Ltd GLAD.NS :
* GETS TENTATIVE APPROVAL FROM USFDA FOR LATANOPROSTENE
BUNOD
OPHTHALMIC SOLUTION
* UPON FINAL APPROVAL, CO MAY BE ELIGIBLE FOR 180 DAYS OF
GENERIC
DRUG EXCLUSIVITY
Source text for Eikon: ID:
Further company coverage: GLAD.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gland Pharma
See all newsIndia Stocks: Indian shares open higher as Fed-hike fears, oil prices ease; financials lead
India Stocks: Indian shares poised to rebound as Fed-hike fears, oil prices ease
Brief: Gland Pharma Approves $21 Million Investment In Gland Pharma Usa
Brief: Fosun Pharma Says Unit Sold Gland Pharma Shares for $294 Mln
India's Gland Pharma gains on successful completion of US FDA probe at Visakhapatnam plant